The blood-brain barrier is the single biggest methodological obstacle in neuropeptide research, and how a given peptide gets past it — or doesn't — shapes almost every downstream decision in a study's design. Semax, Selank, and DSIP are three of the most frequently studied Russian-origin neuropeptides precisely because each was developed with CNS access as a core design consideration, not an afterthought. This article looks at how blood-brain barrier penetration is actually studied for these three compounds, what structural features are believed to support central access, and why administration route is one of the most consequential variables in neuropeptide research design.
Why Blood-Brain Barrier Penetration Is the Defining Research Question for This Peptide Class
Unlike peripherally acting research peptides, where the target tissue is directly accessible from systemic circulation, neuropeptides intended to act on central nervous system receptors have to clear an additional barrier: the tight endothelial junctions and efflux transporters that make up the blood-brain barrier (BBB). For a peptide of even modest size, passive diffusion across this barrier is inefficient, which means BBB penetration — not just receptor affinity — becomes a primary variable researchers have to characterize before any central-activity data can be interpreted. This is the throughline connecting research on Semax, Selank, and DSIP: each is studied not only for its receptor pharmacology, but for the specific route and mechanism by which it reaches central targets at all.
Semax: Structural Features Linked to Central Nervous System Access
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH), and its research profile centers on interactions with brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) signaling pathways. A structural feature frequently cited in Semax research is its Pro-Gly-Pro (PGP) C-terminal tripeptide tail, a motif studied for both independent immunomodulatory signaling and a proposed role in facilitating peptide stability and transport during intranasal administration. Intranasal delivery is the dominant administration route studied for Semax research, and it's the route most closely associated with what researchers describe as measurable central compartment access following dosing — a pattern explored further in our Semax mechanism article.
Selank: The Same Stabilizing Motif, a Different Receptor Target
Selank shares Semax's PGP stabilizing tail but is derived from an entirely different parent sequence — the endogenous immunomodulatory peptide tuftsin — and its research focus centers on GABA-A receptor modulation and anxiolytic-pathway signaling rather than the BDNF/NGF axis Semax engages. The shared PGP motif across both peptides is a useful research parallel: it suggests that this C-terminal structural feature may be doing similar transport-stabilizing work regardless of which receptor system the rest of the peptide sequence is built to engage. Our Semax vs. Selank comparison covers how these two structurally related but functionally distinct peptides are differentiated in comparative research designs, and our Selank mechanism article goes deeper into its specific receptor pharmacology.
DSIP: A Structurally Distinct Neuropeptide With Its Own Access Question
DSIP (Delta Sleep-Inducing Peptide) doesn't share the PGP motif that links Semax and Selank, and its central access is studied through a somewhat different lens — it's a naturally occurring nonapeptide originally isolated from cerebral venous blood during studies of sleep-inducing factors, which means some of the earliest DSIP literature was working from the premise that this peptide is native to central circulation in a way that Semax and Selank, as synthetic ACTH- and tuftsin-derived fragments, are not. DSIP research today focuses on delta-wave sleep architecture and circadian-signaling pathways, and comparative work — including our DSIP vs. Selank comparison — looks at how these two neuropeptides differ in both receptor targets and the administration considerations that follow from their distinct origins.
Intranasal Delivery as a Research Methodology, Not a Convenience
The prevalence of intranasal administration across Semax, Selank, and DSIP research isn't incidental — it reflects an established route for bypassing systemic first-pass metabolism and reaching the CNS via olfactory and trigeminal nerve pathways, which run directly from the nasal epithelium into the central nervous system without requiring the peptide to cross the vascular blood-brain barrier at all. This olfactory-trigeminal transport route is mechanistically distinct from crossing the vascular BBB, and it's a critical distinction for researchers designing a study: a peptide studied via intranasal delivery is often being evaluated for a delivery pathway that circumvents the classical barrier rather than penetrating it directly, and study designs that switch administration routes without accounting for this difference risk comparing pharmacologically non-equivalent conditions.
Efflux Transporters and Enzymatic Degradation as Additional Barriers
Even peptides that do achieve some passive or transporter-mediated crossing of the vascular BBB face two further obstacles once inside brain-adjacent compartments: active efflux transporters that pump many peptide-like substrates back out of the CNS, and peptidase enzymes concentrated at the barrier interface that can degrade a linear peptide sequence before it reaches its target. This is part of why structural stabilization — like the PGP tail shared by Semax and Selank — is such a recurring research theme in this peptide class; a stabilized C-terminus that resists exopeptidase cleavage effectively extends the functional window a peptide has to engage central receptors before it's degraded or effluxed. Researchers characterizing a novel neuropeptide's CNS access typically need to account for all three variables together — barrier crossing, efflux susceptibility, and enzymatic half-life — rather than treating BBB penetration as a single pass/fail property.
What This Means for Comparative Study Design
Because administration route so directly determines whether a study is testing vascular BBB penetration or olfactory-trigeminal bypass, researchers running comparative work across Semax, Selank, and DSIP need to hold route constant as a controlled variable, not just peptide identity and dose. A protocol that administers Semax intranasally and DSIP parenterally in the same comparative study isn't isolating receptor-pharmacology differences — it's introducing a confound at the level of central access itself. This is one of the more common design pitfalls we flag in our broader guide to designing reproducible peptide studies, and it's particularly relevant for this neuropeptide class given how central the delivery-route question is to interpreting any downstream receptor data.
Comparing the Three Peptides at a Glance
- Semax — ACTH-derived heptapeptide with a PGP stabilizing tail; studied for BDNF/NGF pathway engagement; predominantly intranasal administration research.
- Selank — Tuftsin-derived peptide sharing the PGP tail; studied for GABA-A modulation and immune signaling; also predominantly intranasal in the research literature.
- DSIP — Structurally distinct nonapeptide originally isolated from cerebral venous circulation; studied for delta-wave sleep and circadian signaling; administration route varies more across published protocols.
Laid out this way, the pattern is clear: structural similarity (the shared PGP motif in Semax and Selank) tracks with similarity in the administration routes researchers have found effective, while DSIP's distinct origin and structure corresponds to a more varied set of research protocols in the literature.
Sourcing Considerations for Central-Access Neuropeptide Research
Peptide stability during storage and handling has an outsized effect on neuropeptide research specifically, since a peptide that has undergone even partial degradation may show altered — and difficult-to-detect — changes in the structural features believed to support central access, confounding any BBB-penetration data collected downstream. Our guide on peptide storage and handling best practices is worth reviewing alongside this class of research. Semax, Selank, and DSIP are all available in our research-grade catalog with third-party purity documentation, giving researchers a consistent starting point across all three compounds when isolating administration route as the primary experimental variable.
Browse our full research catalog for current neuropeptide availability and batch documentation.
All products are sold strictly for laboratory and in vitro research use only, and are not intended for human or veterinary use, diagnostic procedures, or any application outside a qualified research setting.